4Durelli L, Cocito D, Riccoi A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis : clinical-immunologic correlation[ J]. Neurology ,2003,36:238.
5McDonald WI,Compston A,Edan G,et al.Recommended diagnostic criteria for multiple sclerosis:guidelines from the international panel on the diagnosis for multiple sclerosis[J].Ann Neurol,2001,50 (1):121.
6Hemmer B,Nessler S,Zhou D,at el.Immunopathogenes is and im-munotherapy of multiple sclerosis.Nat C lin Pract Neu ro,l 2006,2:201～211.
7Elenkov IJ.Neurohorm onal-cytokine interactions:implications for in-flammation,common human diseases and well-being[J].NeurochemInt,2008,52:40～51.
8Poser CM,Paty DW,Scheinberg L,et al.New diagnostic criteria for multiple sclerosis:guidelines for research protocols.Ann Neurol, 1983, 13(3):227
9Kurtzke JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale.(EDSS). Neurology, 1983, 33(11):1444
10Noseworthy JH, Lucehinetti C,Rodriguez M, et al. Multiple sclerosis. N Engl J Med,2000,343(13):938
6Herz J,Zipp F,Siffrin V. Neurodegeneration in autoimmune CNS inflammation[J]. Exp Neurol,2010,225(1):9-17.
7Poser CM,Paty DW,Scheinberg L,et al. New diagnostic criteria for multiple sclerosis:Guide lines for reseasch protocols[J]. Ann Neurol,1983,13(3):227-231.
8Kurtzke JF. Rating neurologic impairment inmultiple sclerosis: an expanded disability status scale(EDSS)[J]. Neurology, 1983,33(11):1444-1452.
